IndustryBRIEFS

Swoop Announces Merge with MyHealthTeam 
Swoop, an AI-driven healthcare marketing company, has acquired MyHealthTeam, creator of one of the largest patient social networks in the United States. Together, Swoop and MyHealthTeam aim to improve healthcare outcomes by connecting patients with supportive communities, medically- approved resources, and tools to better manage their conditions. MyHealthTeam’s network of over 62 condition-specific communities for chronic and rare diseases generates privacy-safe, de-identified data, enhancing Swoop’s ability to deliver unique insights. By joining forces, the companies accelerate their shared vision of serving more patients and conditions, creating a transformative impact on healthcare marketing and patient support.

Eric Peacock, Co-founder and CEO of MyHealthTeam said in a press release, “[Our members] connect and chat with other members, they consume the medically-approved articles and videos we create for them, and now we can bring Swoop’s vast depth of claims data, machine learning, and AI capabilities to bear in delivering them information that is personalized based on where they are in their patient journey. You will be seeing us launch communities in many more conditions this year.”

Novo Nordisk Sees Disappointing Results from Phase III Obesity Trial
A clinical trial to test Novo Nordisk’s obesity treatment, CagriSema, included 3417 adults with obesity or overweight with one or more comorbidities and without type 2 diabetes. Participants were randomized to receive subcutaneous CagriSema—which is a fixed-dose combination of the long-acting amylin analogue cagrilintide and the GLP-1 receptor agonist Wegovy (semaglutide)—or the individual components alone or placebo, all administered once-weekly. Early results of this trial showed positive outcomes for participants using CagriSema; however, numbers fell short of expectations during Phase III. Novo plans to start another study in the first half of 2025 to determine how best to boost patients’ doses.

“We are encouraged by the weight-loss profile of CagriSema demonstrating superiority over both [Wegovy] and cagrilintide,” remarked Martin Holst Lange, Executive Vice President for Development at Novo. “With the insights obtained from the REDEFINE 1 trial, we plan to further explore the additional weight-loss potential of CagriSema.”

Designations for Its Speciality Pharmacy
The URAC Specialty Pharmacy 5.0 Accreditation is designed to assess the quality of clinical services provided to payers, manufacturers, and healthcare providers. This accreditation being awarded to EVERSANA, an independent provider of global services to the life sciences industry, confirms that it meets established standards in specialty pharmacy services, focusing on care management and clinical support to benefit patients. EVERSANA also holds the URAC Rare Disease Center of Excellence 3.0 Certification, which acknowledges organizations with expertise in managing rare and complex conditions. This certification was developed in collaboration with rare disease experts, including the National Organization for Rare Disorders, to align with recognized best practices.

“Our team’s commitment to quality and putting the needs of patients first is always unwavering,” said Jim Lang, CEO, EVERSANA. “Receiving these accreditations is a testament to the hard work and dedication of our entire team and validates our efforts to provide exceptional care.”

Ads

You May Also Like

Strategies for Driving New Patient Starts Virtually

According to a survey of 1,000 people conducted by Wakefield Research on behalf of ...

Are We Reaching the End of the Line for PBM Exclusion Lists?

In the rapidly evolving U.S. healthcare landscape, the pharmacy benefit manager (PBM) exclusion lists ...